Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NB9T
|
|||
| Former ID |
DIB003888
|
|||
| Drug Name |
KD018
|
|||
| Indication | Liver cancer [ICD-11: 2C12; ICD-10: C22] | Phase 2 | [1] | |
| Company |
Kadmon pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00730158) A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.